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Abstract Brain-derived neurotrophic factor (BDNF) is
involved in neuronal and glial development and survival.
While neurons and astrocytes are its main cellular source in
the central nervous system (CNS), bioactive BDNF is also
expressed in immune cells and in lesions of multiple
sclerosis and its animal model experimental autoimmune
encephalomyelitis (EAE). Previous data revealed that
BDNF exerts neuroprotective effects in myelin oligoden-
drocyte glycoprotein-induced EAE. Using a conditional
knock-out model with inducible deletion of BDNF, we here
show that clinical symptoms and structural damage are
increased when BDNF is absent during the initiation phase
of clinical EAE. In contrast, deletion of BDNF later in the
disease course of EAE did not result in signiﬁcant changes,
either in the disease course or in axonal integrity. Bone
marrow chimeras revealed that the deletion of BDNF in the
CNS alone, with no deletion of BDNF in the inﬁltrating
immune cells, was sufﬁcient for the observed effects.
Finally, the therapeutic effect of glatiramer acetate, a well-
characterized disease-modifying drug with the potential to
modulate BDNF expression, was partially reversed in mice
in which BDNF was deleted shortly before the onset of
disease. In summary, our data argue for an early window of
therapeutic opportunity where modulation of BDNF may
exert neuroprotective effects in experimental autoimmune
demyelination.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotro-
phin involved in neuronal survival, differentiation and
function as well as axonal growth, modulation of neuronal
activity, and activity-dependent synaptic and dendritic
plasticity in the central nervous system (CNS) (reviewed in
[5]). In several experimental models it was shown to exert
neuroprotective effects [8, 12, 26]. The importance of
BDNF for brain function and maintenance is underscored
by the fact that BDNF-deﬁcient mice already die during the
ﬁrst weeks of life [16]. Even heterozygous mice with 50%
reduced levels of BDNF expression display some behav-
ioral deﬁcits such as aggressiveness, hyperactivity,
hyperphagia and obesity [14, 22, 33].
BDNF also plays a role in autoimmune neuroinﬂam-
mation. Recently, we showed that BDNF indeed has a
neuroprotective role in the myelin oligodendrocyte glyco-
protein (MOG)-induced animal model experimental
autoimmune encephalomyelitis (EAE) [18]. This was par-
ticularly highlighted by a more severe clinical disease
course in mice in which BDNF was conditionally deleted
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macrophages) or in astrocytes/neuronal subpopulations. A
higher amount of axonal damage was detected in these mice
without accompanying alteration of the inﬂammatory pro-
cess [18]. Immune cell-derived BDNFcouldbe of relevance
for the observed protective effects. Indeed, it had been
observedbeforethatthisneurotrophinisexpressedinTcells,
B cells and activated monocytes/macrophages [15, 17].
Moreover, BDNF was found in lesions of multiple sclerosis
(MS) patients and also in EAE [35]. Conditional BDNF-
deﬁcient mice speciﬁcally lacking BDNF in T cells and
monocytes/macrophages displayed a progressive motor
impairment in the late phase of EAE accompanied by an
increase in axonal damage [18]. Furthermore, supplemen-
tation of BDNF by injection of BDNF over-expressing
MOG-speciﬁc T cells resulted in amelioration of EAE
symptoms and reduced axonal damage [18]. These results
supporttheconceptofBDNFbeingamolecularcorrelatefor
a neuroprotective immune response [34].
The disadvantage of the aforementioned approaches is
that they are all based on the permanent ablation of BDNF
early during development. The permanent absence of
BDNF may result in compensatory up-regulation of other
neurotrophines or cytokines or disruption of ﬁne-tuned
regulatory networks within the target cells, thus making it
difﬁcult to isolate the function of BDNF. In this regard it
has been recently reported that heterozygous BDNF ?/-
mice have a diminished peripheral Th1/Th17 antigen-spe-
ciﬁc response after immunization with the myelin basic
protein–proteolipid protein fusion protein MP4 and con-
sequently reduced EAE clinical course and histopathology
[13]. Another disadvantage is that previously a reduction of
BDNF expression within the CNS could only be achieved
in distinct cell types such as astrocytes and as yet poorly
deﬁned neuronal subpopulations but not over the entire
CNS. Finally, these approaches did not allow one to deﬁne
the relevant time period of BDNF action in the course of
EAE to mediate neuroprotective effects. Thus, it is of great
interest to study the role of endogenous BDNF in a setting
where the factor is present during the development and
normal homeostasis but can be speciﬁcally deleted at dif-
ferent time points after EAE induction. In this study, we
employed tamoxifen-inducible Cre mice [9] to yield an
inducible reduction of BDNF levels in cells both of the
CNS and the immune system. In general, we could conﬁrm
the neuroprotective role of BDNF. An induced reduction of
BDNF early (after the priming phase but before the onset
of clinical symptoms) but not later in the course of EAE
resulted in a more severe disease course. These results were
reproduced in bone marrow chimeras with BDNF levels
reduced within the CNS but spared in the hematopoetic
compartment, thus arguing for the relevance of BDNF
production by CNS resident cells for the observed effects.
Materials and methods
Mice
Mice with two loxP sites ﬂanking exon 8 in the BDNF
locus (BDNF
ﬂ/ﬂ) are already described elsewhere [18, 25]
and were bred in our colony in IVC cages. ESR-Cre mice
were purchased from Jackson (stock number 004682) [9].
The two lines were crossed, resulting in ESR-Cre/BDNF
ﬂ/ﬂ
mice (designated as BDNF
ind-/- mice). BDNF
ﬂ/ﬂ litter-
mates served as controls in all experiments. All mice were
backcrossed on a C57BL/6 background for at least ten
generations. Animal experiments were approved by the
responsible authorities in Lower Saxonia.
BDNF deletion and EAE induction
Tamoxifen was purchased from Sigma, Deisenhofen,
Germany and dissolved in sun ﬂower oil. Mice received
three injections of 3 mg (in a total volume of 150 ll) every
other day. In EAE experiments, mice received 3 mg
tamoxifen at days 7, 9 and 11 after immunization (p.i.,
early deletion) or at days 14, 16 and 18 p.i. (late deletion).
In the very ﬁrst control experiment on the effect of
tamoxifen in EAE development, control mice received sun
ﬂower oil only.
EAE induction and scoring are described elsewhere [18,
19]. Brieﬂy, mice were immunized with 50 lgM O G 35–55
in an equal amount of complete Freund’s adjuvant and
received 200 ng pertussis toxin (List Biochemicals,
Campbell, CA, USA) i.p. on days 0 and 2 p.i. The clinical
evaluation was performed on a 10-point scale ranging from
0 (healthy) to 10 (dead) [19]. Mice were scored and
weighed daily. In some experiments, mice were treated
with 500 lg glatiramer acetate s.c. at the time of immu-
nization [18].
Real-time PCR
Mice were killed on the indicated days and mRNA was
prepared from the cerebrum, cerebellum, spinal cord, T
cells and macrophages using an RNeasy Mini kit (Qiagen,
Hilden, Germany). T cells were puriﬁed from a single cell
suspension of splenocytes using a Pan T cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) and mac-
rophages were isolated from the peritoneum by lavage with
two times 2–3 ml ice-cold PBS, followed by plating for 6 h
in medium at 37C, removal of non-adherent cells and
further cultivation overnight at 37C before harvesting and
RNA preparation. cDNA was prepared using superscript
TM
II reverse transcriptase (Invitrogen, Karlsruhe, Germany).
Real-time PCR was used to amplify the coding sequence of
BDNF with mBDNF S (50-GGGCCGGATGCTTCCT
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123T-30), mBDNF AS (50-GCAACCGAAGTATGAAATA
ACCATAG-30), and mBDNF Son (50-TTCCACCAGGTG
AGAAGAGTGATGACCAT-30) as primers. All reactions
were performed on a 7500 Sequence Detection System
(Applied Biosystems, Darmstadt, Germany) with 2 min at
50C, 2 min at 95C and 40–50 cycles with 15 s at 95C
and 1 min at 60C. b-Actin served as endogenous control
for relative quantiﬁcation according to the DDCt-method
[18, 21]. Individual values for each sample are calculated
setting BDNF mRNA levels from the cerebrum of control
mice arbitrarily to ‘‘1’’.
Histology
For the early deletion of BDNF with the tamoxifen treat-
ment starting on day 7 p.i., mice were killed on day 15 p.i.,
perfused with 4% paraformaldehyde and then the lumbar,
thoracal and cervical part of their spinal cord was embed-
ded in parafﬁn. For the late BDNF deletion with tamoxifen
treatment starting on day 14 p.i., the tissue was prepared on
day 30 p.i. In experiments including glatiramer acetate
treatment, histological work-up was performed on day 50
p.i. Spinal cord cross-sections were stained with Luxol fast
Blue (LFB) to assess demyelination. Bielschowsky silver
impregnation or staining for amyloid precursor protein
(APP; 1:1,000, MAB348; Millipore, Schwabach, Germany)
was employed to analyze axonal damage and loss [19]. T
cells were labeled by rat anti-CD3 (Serotec; Wiesbaden,
Germany; 1:300) and macrophages/microglia by rat anti-
mouse Mac-3 (BD Pharmingen; 1:200) and quantiﬁed as
described earlier [19]. Confocal laser scanning microscopy
after double-label immunohistochemistry for 20,30-cyclic
nucleotide 30-phosphodiesterase (CNPase; 1:4,000, Milli-
pore) and the neuroﬁlament antibodies SMI31 or SMI32
(1:1,000, Invitrogen) with anti-mouse Alexa 488- and
Alexa 647-conjugated secondary antibodies or double-label
immunohistochemistry for SMI32 and APP were carried
out according to techniques described elsewhere [18].
Generation of bone marrow chimeric mice
12-Week-old mice were lethally irradiated. Radiation
treatment at a dose rate of 1 Gy/min was delivered by a RS
225 X-Ray Research System (Gulmay Medical Systems,
Camberley, Surrey, UK) operated at 200 kV, 15 mA and
with 0.5-mm Cu ﬁltration. Animals were placed in a cus-
tomized Perspex box and received a total body dose of
12.5 Gy. The following day, bone marrow cells were
removed from the femurs of donor mice, resuspended in
PBS and injected intravenously into the irradiated recipi-
ents at a concentration of 2 9 10
6 cells/mouse. The
chimeric mice were treated with neomycin at a dose of
0.15 mg/ml in their drinking water for 4 weeks. Chimeric
mice were generated either by reconstituting BDNF
ﬂ/ﬂ
mice positive for ESR-Cre or not with CD45.1 congenic
C57BL/6 bone marrow or, alternatively, CD45.1 congenic
C57BL/6 mice with bone marrow from BDNF
ﬂ/ﬂ mice
positive or negative for ESR-Cre. Reconstitution of the
mice was tested 4–5 weeks after bone marrow transfer by
FACS analysis of peripheral blood using antibodies against
CD45.1 and CD45.2 and routinely yielded a reconstitution
efﬁciency of more than 90%. 8 weeks after reconstitution,
EAE was induced by immunization with 50 lgM O G 35–55
and one injection of 200 ng pertussis toxin. For deletion of
BDNF, mice were treated with 3 mg tamoxifen on days 7,
9 and 11 p.i.
Flow cytometry
Lymphocytes were isolated from the spinal cord by density
centrifugation following perfusion of mice with NaCl as
previously described [37]. Subsequently, cells were stained
with the following antibodies: anti-CD3e (145-2C11), anti-
CD4 (RM4-5), anti-CD44 (IM7), anti-CD11a/LFA-1
(2D7), anti-CD8 (53-6.7) (all from BD Biosciences) and
F4/80 (Serotec). The antibodies were either directly labeled
with FITC, PE, PE-Cy7, APC or APC-Cy7 or biotinylated
followed by streptavidin-PE-Cy5. All analyses were per-
formed on a FACS Aria II Sorp device allowing for the
detection of six ﬂuorescent dyes (BD Biosciences).
Histological quantiﬁcation and statistical analyses
For the analysis of EAE disease course, group and time
effects as well as their interaction on EAE disease score
were studied using twofold non-parametric analysis of
variance for repeated measures [3]. In this analysis, we
were particularly interested in the group 9 time interac-
tion. A signiﬁcant interaction indicates a different time
course for the two groups with **P\0.01. The signiﬁ-
cance level for all P values was chosen to be a = 5%. All
analyses were performed using the free software R (version
2.12, http://www.r-project.org).
Histological quantiﬁcation was performed by a blinded
observer by means of overlaying a stereological grid
onto the sections and counting T cells, macrophages/
microglia, APP positive proﬁles and axonal densities on
up to 10–12 lesions per mouse from representative spinal
cord cross-sections comprising cervical, thoracic and
lumbar spinal cord as described previously [18]. Axonal
densities were counted using a 24-point eyepiece from
Olympus (Hamburg, Germany), and the number of points
crossing axons was measured as a fraction of the total
number of points on the sterological grid [27]. Demye-
lination was analyzed semi-automatically with the CellD
software (Olympus).
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groups were calculated using the non-parametric Mann–
Whitney test not assuming Gauss-distributions with
*P\0.05 and **P\0.01.
Results
Rapid deletion of BDNF in the central nervous system
after tamoxifen administration
ESR-Cre mice were crossed with BDNF
ﬂ/ﬂ mice to obtain
BDNF
ind-/- mice in which the gene of BDNF can be
ubiquitously excised after application of the estrogen
receptor modulator tamoxifen [9]. To test for the efﬁciency
and the timing of the BDNF deletion in vivo, BDNF
ind-/-
mice or BDNF
ﬂ/ﬂ mice negative for ESR-Cre (used in the
subsequent EAE experiments as controls) were treated with
tamoxifen (3 9 3 mg every other day i.p.), and BDNF
levels in the cerebrum, cerebellum, spinal cord, spleen-
derived T cells and peritoneal macrophages were deter-
mined by quantitative PCR at days 0 (reference value), 3,
4, 6, 7 and 10 after starting the treatment. In Cre-negative
control mice, the highest mRNA levels for BDNF were
measured in the cerebrum, followed by the cerebellum,
spinal cord, T cells puriﬁed from the spleen and macro-
phages (Fig. 1a). The relative values did not greatly
ﬂuctuate over time, showing that the tamoxifen treatment
per se did not inﬂuence the BDNF expression levels in the
tested organs and cell types (Fig. 1a). In sharp contrast,
BDNF levels in the cerebrum, cerebellum and spinal cord
of BDNF
ind-/- mice dropped at day 4 after tamoxifen
application reaching a minimal plateau level at day 6
(Fig. 1b–d). The BDNF levels were reduced by *75% in
Fig. 1 Reduction of BDNF
mRNA levels in the CNS and T
cells over time after tamoxifen
treatment. BDNF mRNA levels
were measured in BDNF
ind-/-
and naı ¨ve C57BL/6 mice in
different organs/cell types at
various time points after
treatment with tamoxifen at
days 0, 2 and 4 (arrows). a Time
course of BDNF expression in
different organs/cell types of
C57BL/6 control mice. Here,
the individual values were
calculated with the BDNF
mRNA level in the cerebrum at
every time point set arbitrarily
to ‘‘1’’. b–e BDNF mRNA
levels were measured over time
in BDNF
ind-/- mice in the
cerebrum (b), cerebellum (c),
spinal cord (d) puriﬁed T cells
from the spleen (e) and puriﬁed
macrophages from the
peritoneum (f) at the indicated
time points. The mean values
for the respective organs/cell
types in control mice were set as
reference (solid line, a). The
individual values were
calculated with the BDNF
mRNA level in control mice in
the cerebrum set arbitrarily to
‘‘1’’. Data are given as
mean ? SEM where
appropriate
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123the cerebrum (76 ± 7%, days 6–10), cerebellum
(75 ± 5%) and spinal cord (83 ± 9%; Fig. 1b–d). In T
cells, the extent of the reduction of BDNF levels was
similar (70 ± 8%); however, the decrease started slightly
later, reaching minimal plateau levels at day 7 after
tamoxifen treatment (Fig. 1e). In macrophages, the BDNF
expression compared to the CNS was very low (8%) and
did not change signiﬁcantly after tamoxifen application
(Fig. 1f). These data show that the BDNF
ind-/- mice rep-
resent a suitable model for a fast and signiﬁcant reduction
Fig. 2 Exacerbated clinical course of EAE and enhanced histopathol-
ogy after BDNF deletion early during the disease before the onset of
clinical symptoms.BDNF
ind-/-micewere immunizedwith MOG35–55
and treated with tamoxifen at days 7, 9 and 11 p.i. (arrows).
a Representative clinical course of one out of three experiments.
n = 4 for BDNF
ind-/- mice and n = 6 for Cre-negative littermate
controls. Data are given as mean ? SEM. b–f Histological analysis of
thespinalcordofBDNF
ind-/-miceandlittermatecontrolsatday15p.i.
Quantiﬁcation of CD3 positive inﬁltrating T cells (b), Mac-3 positive
inﬁltrating macrophages/activated microglia (c), APP positive proﬁles
(d), axonal densities (e) and demyelination of the white matter (f).
n = 8 for BDNF
ind-/- mice and n = 9 for Cre-negative littermate
controls for histological quantiﬁcation. Data are given as
mean ? SEM. g–p Representative staining of histological parameters
fromBDNF
ind-/-mice(left)andcontrolmice(right).g,hCD3positive
Tcells,i,jMac-3positiveactivatedmacrophages/microglia,k,ldouble
labeling of non-phosphorylated neuroﬁlaments using SMI32 (green)
andAPP(red),m,nBielschowskysilverimpregnationindicatingaxons
and o, p Luxol Fast Blue indicating demyelination. Arrows indicate
positive cells (CD3 or Mac-3), the borders of the lesion in the
Bielschowsky silver impregnation, double-labeled SMI32/APP posi-
tive proﬁles and demyelinated areas. Asterisks indicate SMI32 positive
axons negative for APP. Scale bar is only depicted in p for clarity and
representsthefollowinglength:25 lmforCD3andMac-3staining(g–
j), 10 lm for double labeling SMI32/APP (k, l), 50 lm for axon
staining (m, n) and 250 lm for Luxol Fast Blue (o, p)
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123of BDNF levels in both the CNS and T cells after tamox-
ifen administration.
BDNF deletion in the preclinical phase results
in enhanced clinical course and more severe axonal loss
Estrogens, in general, including the synthetic derivative
tamoxifen, are known to have the capacity to modulate the
susceptibility and severity of mice against EAE induction
[2, 31]. Therefore, we ﬁrst tested if tamoxifen given alone
would inﬂuence the clinical course of EAE in C57BL/6
wild type mice. To this end, EAE was induced in a cohort
of female C57BL/6 mice and the animals were treated
either with tamoxifen (3 mg i.p./treatment) or with sun
ﬂower oil as vehicle at days 7, 9 and 11 p.i. There was no
signiﬁcant difference in onset of disease and clinical score
(mean clinical scores on day 24: 3.7 ± 2.5 for controls vs.
4.5 ± 3.4 for tamoxifen-treated mice, n.s., n = 5–6 per
group), indicating that this tamoxifen treatment protocol
did not inﬂuence the clinical outcome.
Next, we wanted to elucidate whether tamoxifen-
induced BDNF deletion would affect the clinical course
of EAE. Tamoxifen treatment was started on day 7 p.i.,
i.e. during the preclinical phase of EAE. Thus, the
maximal deletion of BDNF levels coincided with the
onset of clinical disease around day 11 p.i. (Fig. 1).
Intriguingly, EAE was signiﬁcantly aggravated in
BDNF
ind-/- compared to control mice without affecting
the onset of disease (Fig. 2a). Histological analysis at
day 15 p.i. revealed that this could not be attributed to
changes in the inﬂammatory response within the EAE
lesions. The levels of leukocyte inﬁltration did not differ
between the groups as indicated by our counts of CD3
positive inﬁltrating T cells (Fig. 2b, g, h) and Mac-3
positive macrophages/activated microglia (Fig. 2c, i, j).
Furthermore, the distribution of the lesions over the
spinal cord did not differ between BDNF
ind-/- and
control mice. These ﬁndings were corroborated by FACS
analysis of cells inﬁltrating the CNS, quantifying the
total number of CD3 positive T cells (Fig. 3a), CD3?
CD4? T helper cells (data not shown) and F4/80?
macrophages/activated microglia (Fig. 3b), which did not
reveal any differences between the groups. Furthermore,
the activation marker CD44 (Fig. 3c) as well as the
integrin LFA-1 (CD11a; data not shown) on CD4? T
helper cells was equally expressed at a high level in both
groups showing that these cells are highly activated.
While there were no differences in immune cell inﬁl-
tration, the extent of axonal damage was signiﬁcantly
enhanced in BDNF
ind-/- mice as reﬂected by a signiﬁ-
cant increase in APP positive proﬁles (Fig. 2d, k, l) and
a parallel reduction in axonal densities in the lesions
(Fig. 2e, m, n). In BDNF
ind-/- mice, there were more
axons double-labeled for APP and SMI32 detecting non-
phosphorylated neuroﬁlaments that serve as marker for
acutely damaged axons (Fig. 2k, l). In addition, in these
mice, we also found more pronounced demyelination,
evaluated by Luxol Fast Blue staining (Fig. 2f, o, p).
The relative distribution of demyelination in the lumbar,
thoracic and cervical part of the spinal cord was similar
between the groups (data not shown). These data indicate
that the presence of BDNF in the early clinical phases of
EAE is important for the limitation of inﬂammation-
mediated structural damage.
Fig. 2 continued
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123BDNF deletion after the peak of EAE inﬂuences
neither the clinical course nor the extent of axonal
damage
These data raised the question of whether BDNF ablation
induced after the peak of disease would similarly inﬂuence
the disease severity and neuronal integrity. Therefore, we
started to treat BDNF
ind-/- and control mice with tamox-
ifen at day 14 p.i. According to our earlier observations
with this treatment approach (Fig. 1), BDNF levels would
be expected to decline at day 18 p.i., i.e. at a time point
when a slight recovery of the mice from the peak of disease
can usually be observed. Notably, BDNF
ind-/- mice only
developed a minor disease exacerbation that did not reach
statistical signiﬁcance when compared to tamoxifen-treated
control littermates (Fig. 4a). The histological analyses on
day 30 p.i. did not show signiﬁcant differences in the
numbers of inﬁltrating CD3 positive T cells (Fig. 4b, f, g)
or Mac-3 positive macrophages/activated microglia
between BDNF
ind-/- mice and controls (Fig. 4c, h, i)
Furthermore, the axonal damage assessed by SMI32/APP
double-labeled proﬁles (Fig. 4j, k) and quantiﬁcation of
axonal densities (Fig. 4d, l, m) and the extent of demye-
lination (Fig. 4e, n, o) were similar. Thus, in contrast to the
ﬁndings obtained after early treatment, BDNF deletion late
in the course of clinical EAE does not signiﬁcantly inﬂu-
ence the severity of disease or parameters of tissue
destruction.
The therapeutic efﬁcacy of glatiramer acetate is limited
after inducible BDNF deletion
In order to test if the disease aggravating effects observed
during early treatment with tamoxifen were indeed due to
the ablation of BDNF, we performed treatment studies with
glatiramer acetate. This well-established disease-modifying
drug in MS is known to exert neuroprotective effects in
MOG35–55-induced EAE via modulation of BDNF [18].
Therefore, BDNF
ind-/- mice were treated with glatiramer
acetate at the time of immunization and additionally with
tamoxifen starting at day 7 p.i. In this particular experi-
ment, the control mice not treated with glatiramer acetate
displayed a fulminant disease course and had to be killed
for ethical reasons at an early time point (Fig. 5a). As
expected, glatiramer acetate signiﬁcantly protected wild-
type mice from EAE (Fig. 5a). In contrast, glatiramer
acetate treatment in BDNF
ind-/- mice was signiﬁcantly
less effective and mice displayed a signiﬁcant exacerbation
of the disease in the late phase (Fig. 5a). When compared
to controls, the histological examination revealed a less
pronounced protection of myelin and axons in BDNF
ind-/-
mice (Fig. 5b, c). These results were further corroborated
by morphological analyses obtained by laser scanning
confocal microscopy. Double staining for CNPase as
marker for myelin and neuroﬁlaments revealed that
BDNF
ind-/- mice treated with glatiramer acetate and
tamoxifen displayed a reduced immunoreactivity for
SMI31 detecting phosphorylated neuroﬁlaments as marker
of intact axons compared with controls (Fig. 5d, e). In
contrast, we observed an enhanced immunoreactivity for
SMI32 detecting non-phosphorylated neuroﬁlaments and
serving as marker for damaged axons (Fig. 5f, g).
Enhanced motor impairment after early BDNF deletion
in bone marrow chimeric mice
We ﬁnally investigated whether the deletion of BDNF is
critical in CNS resident cells or in CNS-inﬁltrating lym-
phocytes. To this end, we generated bone marrow
chimeras. BDNF
ind-/- mice or Cre-negative controls were
lethally irradiated and reconstituted with wild-type bone
marrow. Eight weeks later, EAE was induced by
Fig. 3 Analysis of inﬁltrating cells into the spinal cord using ﬂow
cytometry. BDNF
ind-/- mice were immunized with MOG35–55 and
treated with tamoxifen at days 7, 9 and 11 p.i. At the peak of disease
mice were killed and perfused with NaCl. Lymphocytes were puriﬁed
from dissected spinal cords, microscopically enumerated and stained
for CD3, CD4, CD8, F4/80, CD44 and CD11a followed by ﬂow
cytometric analysis. Subsequently, absolute numbers of immune cell
populations were calculated. There were no signiﬁcant differences in
absolute numbers of inﬁltrating T cells (a), macrophages/activated
microglia (b) or the expression levels of the activation marker CD44
on CD3? CD4? T cells (c). All values are depicted as mean ± SEM
(n = 5 per group)
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123immunization with MOG35–55, and all mice were treated
with tamoxifen starting at day 7 p.i., the time point where
the most pronounced effect was seen in the previous
experiments. In this setting, BDNF can only be deleted in
resident cells from the CNS but not in lymphocytes derived
from the wild-type bone marrow. Again, chimeric
BDNF
ind-/- mice exhibited a signiﬁcantly enhanced motor
impairment, thus mirroring the phenotype of BDNF
ind-/-
mice treated with tamoxifen (Fig. 6a). In a complementary
approach, bone marrow chimeric mice were generated
using wild-type mice as recipients and BDNF
ind-/- mice
and appropriate controls as donors. These mice, in which
BDNF can be deleted only in cells of the hematopoietic
system, did not suffer from aggravated EAE but rather
displayed a slightly milder disease course in the early phase
(Fig. 6b) resembling EAE seen in mice in which BDNF
Fig. 4 No difference in clinical course and histopathology of EAE
after BDNF deletion later in the disease course. BDNF
ind-/- mice
were immunized with MOG35–55, and treated with tamoxifen at days
14, 16 and 18 p.i. (arrows). a Clinical course of a pool of two
experiments. n = 12 for BDNF
ind-/- mice and n = 15 for Cre-
negative littermate controls. Data are given as mean ? SEM. b–
e Histological analysis of spinal cord cross-sections from BDNF
ind-/-
mice and littermate controls at day 30 p.i. of CD3 positive inﬁltrating
T cells (b), Mac-3 positive inﬁltrating macrophages/activated
microglia (c), axonal densities (d) and demyelination of the white
matter (e). n = 6 for BDNF
ind-/- mice and n = 10 for Cre-negative
littermate controls. Data are given as mean ? SEM. f–o Representa-
tive staining of histological parameters from BDNF
ind-/- mice (left)
and control mice (right) for CD3 positive T cells (f, g), Mac-3
positive activated macrophages/microglia (h, i), double labeling of
non-phosphorylated neuroﬁlaments using SMI32 (green) and APP
(red)( j, k), Bielschowsky silver impregnation indicating axons (l, m),
and Luxol Fast Blue indicating demyelination (n, o). Arrows indicate
positive cells (CD3 or Mac-3), the borders of the lesion in the
Bielschowsky silver impregnation, double-labeled SMI32/APP posi-
tive proﬁles and demyelinated areas. Asterisks indicate SMI32
positive axons negative for APP. Scale bar is only depicted in o for
clarity and represents the following length: 25 lm for CD3 and Mac-3
staining (f–i), 10 lm for double labeling SMI32/APP (j, k), 50 lm for
axon staining (l, m) and 250 lm for Luxol Fast Blue (n, o)
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123was deleted in both T cells and macrophages/monocytes
[18]. In conclusion, CNS resident cells appear to be a major
source of biologically relevant BDNF in autoimmune
demyelination.
Discussion
BDNF is a neurotrophic factor with pleiotropic properties
within the nervous system and is involved in neuronal
Fig. 5 BDNF deletion leads to
partial reversion of the
therapeutic effect of glatiramer
acetate. BDNF
ind-/- mice were
immunized with MOG35–55 in
the absence or presence of
glatiramer acetate and treated
with tamoxifen at days 7, 9 and
11 p.i. (arrows). a Clinical
course of MOG-EAE. n = 5–6
for BDNF
ind-/- mice and Cre-
negative littermate controls with
and without glatiramer acetate
treatment. Data are given as
mean ? SEM. Histological
analysis and blinded
stereological quantiﬁcation was
performed on day 50 p.i. for
axonal densities (b) and
demyelination (c). Confocal
laser scanning microscopy was
performed after staining for
CNPase (red) and
phosphorylated neuroﬁlaments
using SMI31 (green; d, e)o r
non-phosphorylated
neuroﬁlaments using SMI32
(green; f, g). Note that in
BDNF
ind-/- mice axons are
swollen and appear thicker than
those of controls. Scale bar is
only depicted in g for clarity
and is 10 lm
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123survival and differentiation as well as synaptic plasticity
[5]. In addition, BDNF is expressed in activated immune
cells (T cells, B cells and monocytes) [15] and is histo-
logically observed to be in close proximity to lesions in the
CNS of MS patients [35], suggesting a possible protective
role in this setting. Indeed, we and others showed that
BDNF is neuroprotective in MOG35–55-induced EAE [18,
23, 24].
Our observations extend these previous studies by
addressing (a) the time point at which BDNF action seems
to be critical for its neuroprotective effects in EAE and
(b) the relevant tissue (CNS vs. hematopoetic system)
responsible for BDNF production. To this end, we
employed a conditional knockout system with a signiﬁcant
reduction in global BDNF levels by administration of
tamoxifen. Notably, the neuroprotective effect was most
prominent when BDNF was deleted early, i.e. at a time
point after T cell priming (to avoid possible immunological
effects) and shortly before the occurrence of ﬁrst clinical
symptoms. In contrast, BDNF deletion after the ﬁrst peak
of disease resulted in only marginal effects on the clinical
disease course and on histopathological parameters of
tissue destruction. These data suggest that the neuropro-
tective effects of BDNF in the experimental model of MS
are particularly relevant during the early phase of EAE.
This is in line with the observations both in EAE and MS
patients that key features of neurodegeneration already
occur in early disease phases [10, 11, 36]. Thus, it seems
that neuro-axonal injury during this early phase may also
impact on the functional outcome of disease at later time
points, and that an interference with neurodegeneration
during this critical phase, i.e. by survival-promoting neu-
rotrophins such as BDNF as in the current study, is a
prerequisite for BDNF’s action. Importantly, early deletion
of BDNF also affected the efﬁcacy of glatiramer acetate
treatment which was previously shown to exert neuropro-
tective effects via BDNF [18]. This conﬁrms that the
observed effects are indeed mediated via the reduction of
BDNF levels and not secondary to tamoxifen treatment.
Our experiments using bone marrow chimeras in which
BDNF
ind-/- mice were reconstituted with wild-type bone
marrow revealed that CNS-derived BDNF is even more
critical than immune cell-derived BDNF for a neuropro-
tective effect in autoimmune demyelination. This is in line
with the results observed for tissue-speciﬁc deletion of
BDNF. The deletion of BDNF in astrocytes/neuronal sub-
populations resulted in an enhanced motor impairment
early in the course of EAE, whereas BDNF deletion in
immune cells resulted in a similar phenotype only at much
later time points [18]. Together, the data argue for an
intrinsic self-protective mechanism of the CNS that is
already called into action at a very early time point of
autoimmune inﬂammation.
The deletion of BDNF was highest in the CNS followed
byTcellswhilereductionofBDNFlevelswasnotdetectable
in macrophages. Of note, Cre expression as measured by
real-time PCR was ten times higher in the CNS compared to
the thymus and even lower in the spleen, giving an expla-
nation for the weaker recombination of cells in these organs
(unpublished results). When compared with CNS tissue and
T cells, macrophages express BDNF at low levels [17], thus
making the detection of recombination difﬁcult.
Since MS and EAE are reported to be inﬂuenced by
estrogen receptor signaling [29, 30], we wondered whether
tamoxifen treatment per se impacts on the disease course of
EAE. In our control experiments using female C57BL/6
mice, we could not detect signiﬁcant differences between
the clinical EAE course of mice treated with tamoxifen at
days 7, 9 and 11 p.i. and controls only receiving sun ﬂower
oil. Yet, upon administration of tamoxifen as early as
14 days prior to immunization, we found protective effects
of tamoxifen in EAE (data not shown) which is in line with
previous observations by Bebo et al. [2] and precludes an
unambiguous analysis of an even earlier tamoxifen-
induced BDNF deletion during EAE. While tamoxifen may
Fig. 6 Exacerbation of EAE after early BDNF deletion in bone
marrow chimeric mice. Bone marrow chimeric mice were generated
using either BDNF
ind-/- mice or control mice as recipients and wild
type mice as donors (a) or vice versa using wild-type mice as
recipients and either BDNF
ind-/- mice or control mice as donors (b).
After immunization with MOG35–55, BDNF was deleted by tamoxifen
treatment at days 7, 9 and 11 p.i. (arrows). The clinical course is
shown with n = 4 for BDNF
ind-/- mice and n = 7 for Cre-negative
littermate controls (a) and a data pool of two independent experiments
with n = 9 for BDNF
ind-/- mice and n = 14 for Cre-negative
littermate controls (b). Data are given as mean ? SEM
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123reduce T cell proliferation and MHC class II expression
early during EAE, it seems conceivable that such immu-
nomodulatory effects are only of minor importance if
tamoxifen treatment is started as late as day 7 p.i. In
addition, in our experimental setting all mice were treated
with tamoxifen including controls. Therefore, potential
minor effects of tamoxifen on the immune response would
affect all animals and do not explain our observations.
Mice heterozygous for BDNF display behavioral
abnormalities such as learning deﬁciencies [20], aggres-
siveness, hyperactivity and also hyperphagia accompanied
by obesity [14, 22]. Furthermore, mice in which BDNF was
deleted in parts of the CNS shortly after birth using a
conditional system showed higher levels of anxiety and
obesity [33]. A recent approach resulting in a more global
deletion of BDNF in the CNS starting around birth also
resulted in features of hyperactivity and obesity [32]. In the
current study, we could conﬁrm these observations.
BDNF
ind-/- mice exhibited behavioral abnormalities
starting 3–4 days after the ﬁrst tamoxifen treatment. This
included hyperactivity, restlessness, sudden jumps and
somersaults, as already described by others [14, 33]. Most
strikingly, these symptoms were even evident in mice
suffering from EAE (unpublished observations). In addi-
tion, tamoxifen-treated BDNF
ind-/- mice gained weight
even in the presence of hyperactivity. Over time, their body
weight was signiﬁcantly higher than that of their control
littermates (unpublished observations). These observations
are well in line with the concept that physiological BDNF
levels are not only necessary during the development but
also play a steady-state role in the regulation of motor
activity and eating behavior in the adult mouse.
While BDNF is well known as a survival factor for neu-
rons, the molecular mechanisms linking BDNF to axonal
damagearenotyetwelldeﬁned.BDNFhasbeendescribedas
acting on immune cells, e.g. regulating IL-2 production of T
cells [1] and MHC II expression of microglia [28], presum-
ably via activation of the transcription factor ‘‘cAMP
responsive element binding protein’’ (CREB) [4]. In neu-
rons,CREBisamajormediatorintheBDNF-TrkBsignaling
cascade activated either via the PLCc/Ca
2?/CamK IV or,
alternatively, through the Ras/ERK/Rsk pathway and regu-
lates BDNF-induced gene expression [7]. Whether CREB is
really instrumental for the described axonal preservation in
EAEandwhatrole,ifany,GAplaysinthispathwaydeserves
further investigation.
In summary, BDNF plays a protective role in the disease
course of EAE. In particular, it is BDNF produced by the
CNS that is the main source for BDNF’s immediate neu-
roprotective action while BDNF from inﬁltrating immune
cells seems to play, if any, rather a minor role. Moreover,
BDNF is critically involved already early in the disease
course at a time when the ﬁrst symptoms occur and the
inﬂammatory assault to the CNS is initiated. This obser-
vation may have important implications on the timing of
neuroprotective drug treatment strategies in MS patients.
Our data argue for a therapeutic window of opportunity not
only for immunomodulatory drugs [6] but also for neuro-
protective treatment approaches aiming at the modulation
of neurotrophic factors.
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